Parkinson’s Disease

Volume 2014 (2014), Article ID 467131, 8 pages

http://dx.doi.org/10.1155/2014/467131

Clinical Study

Minimal Clinically Important Difference in Parkinson’s Disease as Assessed in Pivotal Trials of Pramipexole Extended Release

Robert A. Hauser,¹ Mark Forrest Gordon,² Yoshikuni Mizuno,³ Werner Poewe,⁴ Paolo Barone,⁵ Anthony H. Schapira,⁶ Olivier Rascol,⁷ Catherine Debieuvre,⁸ and Mandy Fräßdorf⁹

¹University of South Florida, Parkinson’s Disease and Movement Disorders Center, Byrd Institute, National Parkinson Foundation Center of Excellence, Tampa, FL 33613, USA

²Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877, USA

³Department of Neurology, Juntendo University School of Medicine, Tokyo 113-8421, Japan

⁴Department of Neurology, Innsbruck Medical University, Innsbruck, Austria

⁵Center for Neurodegenerative Diseases, Department of Medicine and Surgery, University of Salerno, Salerno, Italy

⁶Department of Clinical Neurosciences, University College London Institute of Neurology, London, UK

⁷Clinical Investigation Center, INSERM CIC-9302 and UMR-825 and Departments of Clinical Pharmacology and Neurosciences, Toulouse University Hospital, Toulouse, France

⁸Boehringer Ingelheim France S.A.S., Reims, France

⁹Boehringer Ingelheim Pharmaceuticals, GmbH & Co. KG, Ingelheim, Germany

Received 31 October 2013; Accepted 28 January 2014; Published 1 April 2014

Academic Editor: Francisco Grandas

Copyright © 2014 Robert A. Hauser et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Background. The minimal clinically important difference (MCID) is the smallest change in an outcome measure that is meaningful for patients. Objectives. To calculate the MCID for Unified Parkinson’s Disease Rating Scale (UPDRS) scores in early Parkinson’s disease (EPD) and for UPDRS scores and “OFF” time in advanced Parkinson’s disease (APD). Methods. We analyzed data from two pivotal, double-blind, parallel-group trials of pramipexole ER that included pramipexole immediate release (IR) as an active comparator. We calculated MCID as the mean change in subjects who received active treatment and rated themselves “a little better” on patient global impression of improvement (PGI-I) minus the mean change in subjects who received placebo and rated themselves unchanged. Results. MCIDs in EPD (pramipexole ER, pramipexole IR) for UPDRS II were −1.8 and −2.0, for UPDRS III −6.2 and −6.1, and for UPDRS II + III −8.0 and −8.1. MCIDs in APD for UPDRS II were −1.8 and −2.3, for UPDRS III −5.2 and −6.5, and for UPDRS II + III −7.1 and −8.8. MCID for “OFF” time (pramipexole ER, pramipexole IR) was −1.0 and −1.3 hours. Conclusions. A range of MCIDs is emerging in the PD literature that provides the basis for power calculations and interpretation of clinical trials.

1. Introduction

Large randomized clinical trials can demonstrate statistically significant differences on outcome measures that may be small and of uncertain relevance as to whether patients actually feel improved [1–3]. The Movement Disorder Society Task Force for Rating Scales for Parkinson’s Disease encouraged the identification of a threshold, or the smallest difference on the Unified Parkinson’s Disease Rating Scale (UPDRS), that represents the “minimal clinically relevant difference” [4]. The US Food and Drug Administration also expressed the need to determine minimally important differences on measures used to support the labelling claims of medical products [5].

Several investigators have reported assessments of the minimal clinically important difference (MCID) in PD [2, 3, 6, 7]. Although the methodology varied, most studies assessed MCID based on mean change in UPDRS scores in patients defined as minimally improved compared to baseline using the Clinician-rated Global Impression of Improvement (CGI-I) scale. There is a paucity of MCID data based on a patient-rated tool, such as the Patient-rated Global Impression of Improvement (PGI-I). Most of the published MCID data focus on patients with early PD and come from clinical trials of ropinirole or rasagiline [3, 6], but not pramipexole.

Using both PGI-I and CGI-I as anchors, we describe MCID data from two placebo-controlled studies of pramipexole extended release (ER) in patients with early PD (EPD) and advanced PD (APD). Both studies used pramipexole immediate release (IR) as the active comparator. Based on these data, we present several novel findings, not previously explored, including (1) MCID for UPDRS scores in APD, (2) “substantial clinical differences” for UPDRS scores in EPD, and UPDRS scores and “OFF” time for APD, (3) evaluation of the symmetry between calculated minimal important improvement and minimal important worsening, and (4) correlations between PGI-I/CGI-I and changes in UPDRS scores and OFF times.

2. Methods

We analyzed data from two pivotal, double-blind, double-dummy, placebo-controlled, parallel-group trials of pramipexole ER. One study (248.524, clinical trial identifier number NCT00479401 at ClinicalTrials.gov) [8, 9] was conducted in subjects with EPD who were Hoehn and Yahr (H-Y) stage 1–3, had disease duration ≤ 5 years, were at least 30 years old at the time of diagnosis, had reached a level of disability requiring initiation of dopaminergic therapy, and were not receiving levodopa or dopamine agonists. The other study (248.525, clinical trial identifier number NCT00466167 at ClinicalTrials.gov) [10] was conducted in subjects with APD who were H-Y stage 2–4 during “on” time, were diagnosed ≥ 2 years before entry, were at least 30 years old, were receiving a stable regimen of levodopa at an optimized dosage, and were experiencing motor fluctuations with at least 2 hours of “OFF” time per day. In both studies, additional antiparkinsonian medications other than dopamine agonists and levodopa were permitted provided that the dosages were stable. In each study, subjects were randomized to treatment with placebo, pramipexole ER, or pramipexole IR. In the EPD study, the randomization ratio was 1 : 2 : 2 and the treatment duration was 33 weeks. In the APD study, the randomization was 1 : 1 : 1 and the treatment duration was 18 weeks. In both studies, the daily dosage of double-blind study medication was up-titrated as tolerated until a response was reached that was judged by the investigator to be at least satisfactory and the subject rated himself at least “a little better,” or until the maximum tolerated or allowed dosage (4.5 mg/day) was reached. Subjects then entered a maintenance phase in which the dosage remained unchanged until the end of trial.

In the EPD study, 539 subjects were randomized. Two primary outcomes were demonstrated: superiority of pramipexole ER over placebo after 18 weeks of treatment and noninferiority between pramipexole ER and IR after 33 weeks of treatment. The primary outcome measure was the change from baseline in UPDRS parts II + III, and secondary outcome measures included responder rates based on PGI-I and CGI-I. Details have been published elsewhere [8, 9].

In the APD trial, 517 subjects were randomized. The primary outcome (change from baseline in UPDRS II + III) demonstrated superiority of pramipexole ER over placebo after 18 weeks of treatment. Secondary outcome measures included change in OFF time based on patient diaries and responder rates based on PGI-I and CGI-I. Details are available elsewhere [10].

For both studies, we analyzed efficacy outcome data from the population of all subjects who received study medication and had a postbaseline efficacy assessment with last observation carried forward for missing data. For the EPD study, mean changes in UPDRS scores were calculated for each PGI-I and CGI-I score at 33 weeks. Changes from baseline were considered separately for UPDRS parts II, III, and II + III. For the APD study, mean changes in OFF time and UPDRS scores were calculated for each PGI-I and CGI-I score at 18 weeks. Changes from baseline were considered separately for UPDRS parts II (mean of UPDRS part II ON and OFF), III, and II + III. In accordance with Hauser and Auinger’s previously published methodology [3], we calculated MCID as the mean change in subjects who received active treatment and rated themselves “a little better” minus the mean change in subjects who received placebo and rated themselves unchanged. We also analyzed correlations between CGI-I/PGI-I and change in UPDRS parts II, III, and II + III in the EPD and APD studies and between CGI-I/PGI-I and change in OFF time in the APD study using Spearman correlation coefficients.

The early and advanced trials were conducted between May 2007 and November 2008 at 94 and 76 centers worldwide, respectively [8–10]. Appropriate institutional review boards and ethics committees approved the studies, and all patients provided written informed consent.

3. Results

Mean changes in UPDRS II, III, and II + III scores, corresponding to each of the PGI-I and CGI-I ratings for each treatment group, are reported in Table 1 for the EPD study and Table 2 for the APD study. In the EPD study, for subjects rating themselves “a little better,” mean changes in UPDRS II, III, and II + III scores in the pramipexole ER group were −2.4, −7.9, and −10.3 and in the pramipexole IR group −2.6, −7.8, and −10.4. Across a range of PGI ratings, mean changes in UPDRS II + III scores for the pramipexole ER group were −9.0 for “very much better,” −14.4 for “much better,” −10.3 for “a little better,” −8.9 for “no change,” −2.9 for “a little worse,” and 1.3 for “much worse.” In the pramipexole IR group, mean changes in UPDRS II + III scores were −19.0 for “very much better,” −12.6 for “much better,” −10.4 for “a little better,” −6.3 for “no change,” −1.9 for “a little worse,” and 2.5 for “much worse.” Only one subject taking pramipexole ER and no subject taking pramipexole IR self-rated as “very much worse.” Mean changes in UPDRS II, III, and II + III scores for placebo-treated subjects who rated themselves unchanged were −0.6, −1.7, and −2.3.

Table 1: Mean changes in UPDRS II, III, and II+III scores according to PGI-I and CGI-I ratings by treatment group in the early PD study.

PGI-I
(%)
UPDRS II
UPDRS III
UPDRS II+III
        CGI-I
(%)
UPDRS II
UPDRS III
UPDRS II+III

Pramipexole ER    

Very much better
10 (5%)
−3.5 (3.3)
−5.5 (4.9)
−9.0 (6.4)
Very much improved
15 (7%)
−2.7 (3.8)
−8.1 (7.6)
−10.9 (10.2)

Much better
63 (30%)
−3.6 (3.0)
−10.7 (8.4)
−14.4 (10.0)
Much improved
76 (38%)
−3.8 (3.1)
−11.3 (8.5)
−15.1 (10.2)

A little better
59 (28%)
−2.4 (3.3)
−7.9 (8.4)
−10.3 (10.6)
Minimally improved
71 (34%)
−2.5 (2.7)
−7.0 (5.7)
−9.4 (7.1)

No change
45 (21%)
−2.6 (2.8)
−6.3 (5.7)
−8.9 (7.4)
No change
33 (16%)
−0.9 (2.4)
−2.3 (5.4)
−3.3 (6.8)

A little worse
22 (10%)
0.1 (3.0)
−3.0 (4.9)
−2.9 (6.9)
Minimally worse
12 (6%)
1.9 (3.3)
1.5 (6.8)
3.4 (8.8)

Much worse
12 (6%)
0.8 (3.7)
0.6 (6.7)
1.3 (9.4)
Much worse
3 (1%)
2.7 (5.5)
2.3 (5.7)
5.0 (10.5)

Very much

worse
1 (0.5%)
0
7
7
Very much worse
0

Pramipexole IR    

Very much better
8 (4%)
−5.4 (2.6)
−13.6 (7.5)
−19.0 (9.6)
Very much improved
14 (7%)
−5.5 (2.5)
−14.1 (8.1)
−19.6 (8.9)

Much better
61 (29%)
−3.8 (3.7)
−8.8 (8.3)
−12.6 (10.7)
Much improved
81 (39%)
−3.9 (3.6)
−10.3 (8.5)
−14.1 (10.6)

A little better
73 (35%)
−2.6 (3.3)
−7.8 (8.5)
−10.4 (10.1)
Minimally improved
66 (32%)
−2.1 (3.1)
−5.6 (6.7)
−7.7 (8.2)

No change
44 (21%)
−1.6 (2.9)
−4.8 (8.3)
−6.3 (9.9)
No change
34 (17%)
−0.5 (2.3)
−1.9 (6.8)
−2.4 (7.9)

A little worse
17 (8%)
0.0 (3.0)
−1.9 (5.5)
−1.9 (7.8)
Minimally worse
9 (4%)
0.0 (2.8)
1.6 (5.6)
1.6 (7.2)

Much worse
4 (2%)
0.3 (3.3)
2.3 (4.8)
2.5 (7.0)
Much worse
2 (1%)
3.0 (1.4)
3.5 (2.1)
6.5 (0.7)

Very much worse
0

Very much worse
0

Placebo     

Very much better
4 (4%)
−1.8 (3.0)
−7.0 (6.7)
−8.8 (6.4)
Very much improved
2 (2%)
−2.5 (3.5)
−6.0 (4.2)
−8.5 (7.8)

Much better
18 (18%)
−3.4 (2.8)
−6.7 (5.9)
−10.1 (6.9)
Much improved
28 (28%)
−2.3 (2.8)
−6.8 (4.4)
−9.1 (5.1)

A little better
34 (33%)
−1.0 (3.5)
−5.2 (8.4)
−6.2 (10.2)
Minimally improved
31 (30%)
−1.3 (3.4)
−7.3 (7.6)
−8.5 (9.0)

No change
34 (33%)
−0.6 (3.2)
−1.7 (7.1)
−2.3 (8.8)
No change
29 (28%)
−0.5 (3.5)
0.7 (5.7)
0.2 (7.9)

A little worse
10 (10%)
1.7 (3.7)
1.8 (3.3)
3.5 (6.3)
Minimally worse
11 (11%)
1.8 (4.1)
4.1 (6.1)
5.9 (9.5)

Much worse
3 (3%)
0.3 (2.3)
5.3 (2.5)
5.7 (4.7)
Much worse
1 (1%)
2
13
15

Very much worse
0

Very much worse
0

Presented as the mean change in the UPDRS scores (standard deviations).

PGI-I: Patient-rated Global Impression of Improvement; CGI-I: Clinician-rated Global Impression of Improvement.

Table 2: Mean changes in UPDRS II, III, and II+III scores according to PGI-I and CGI-I ratings by treatment group in the advanced PD study.

PGI-I
(%)
UPDR II
UPDRS III
UPDRS II+III
        CGI-I
(%)
UPDRS II
UPDRS III
UPDRS II+III

Pramipexole ER    

Very much better
9 (6%)
−3.7 (2.5)
−12.7 (5.5)
−16.4 (7.2)
Very much improved
9 (6%)
−4.3 (2.5)
−13.3 (6.6)
−17.7 (8.8)

Much better
51 (32%)
−4.6 (4.3)
−11.2 (12.7)
−15.8 (15.9)
Much improved
69 (43%)
−4.3 (4.4)
−11.2 (11.3)
−15.5 (14.4)

A little better
66 (41%)
−2.8 (3.8)
−8.2 (8.8)
−11.1 (11.2)
Minimally improved
51 (32%)
−2.0 (3.9)
−7.7 (9.3)
−9.7 (11.9)

No change
20 (12%)
−2.5 (4.0)
−6.8 (9.8)
−9.3 (12.5)
No change
22 (14%)
−3.3 (3.6)
−7.8 (6.6)
−11.1 (7.9)

A little worse
13 (8%)
−0.9 (4.4)
−6.9 (6.4)
−7.8 (8.2)
Minimally worse
7 (4%)
−0.5 (2.7)
1.6 (9.7)
1.1 (10.2)

Much worse
1 (0.6%)
−1.0
6.0
5.0
Much worse
2 (1%)
0.3 (6.7)
−1.0 (0.0)
−0.8 (6.7)

Very much worse
1 (0.6%)
5.0
−1.0
4.0
Very much worse
0

Pramipexole IR    

Very much better
10 (6%)
−6.3 (3.5)
−16.9 (12.9)
−23.2 (13.9)
Very much improved
11 (7%)
−5.4 (3.4)
−14.5 (7.1)
−20.0 (6.8)

Much better
66 (38%)
−4.9 (4.2)
−11.9 (9.9)
−16.8 (12.0)
Much improved
77 (46%)
−5.2 (4.3)
−12.9 (10.4)
−18.0 (12.6)

A little better
55 (32%)
−3.3 (4.1)
−9.5 (9.8)
−12.8 (12.9)
Minimally improved
55 (33%)
−3.0 (3.5)
−8.4 (9.0)
−11.3 (11.4)

No change
27 (16%)
−34.1 (4.2)
−6.0 (6.4)
−9.2 (8.6)
No change
19 (11%)
−2.5 (4.0)
−2.8 (7.4)
−5.3 (9.7)

A little worse
10 (6%)
−2.0 (2.4)
−3.2 (10.4)
−5.2 (10.9)
Minimally worse
4 (2%)
−0.6 (5.0)
−6.0 (3.6)
−6.6 (8.0)

Much worse
4 (2%)
0.1 (6.0)
1.8 (10.1)
1.9 (15.8)
Much worse
3 (2%)
−0.5 (7.1)
2.3 (9.3)
1.8 (16.1)

Very much worse
0

Very much worse
0

Placebo     

Very much better
3 (2%)
−8.3 (8.8)
−11.0 (9.5)
−19.3 (18.3)
Very much improved
6 (4%)
−6.4 (6.3)
−9.5 (6.8)
−15.9 (13.1)

Much better
44 (26%)
−4.0 (5.8)
−8.9 (13.8)
−12.9 (18.6)
Much improved
50 (29%)
−3.8 (5.4)
−9.8 (12.1)
−13.6 (16.3)

A little better
65 (37%)
−1.9 (3.6)
−3.8 (7.2)
−5.6 (8.6)
Minimally improved
66 (39%)
−1.8 (3.7)
−3.8 (9.0)
−5.7 (10.8)

No change
43 (25%)
−1.0 (3.9)
−3.0 (6.7)
−4.0 (9.0)
No change
31 (18%)
−1.1 (4.7)
−1.0 (6.0)
−2.1 (7.9)

A little worse
12 (7%)
0.1 (4.5)
−1.3 (13.5)
−1.1 (15.6)
Minimally worse
15 (9%)
0.0 (3.3)
0.9 (6.2)
1.0 (7.9)

Much worse
7 (4%)
0.1 (5.6)
−1.1 (3.9)
−1.1 (8.5)
Much worse
3 (2%)
5.3 (4.0)
3.0 (4.4)
8.3 (8.3)

Very much worse
0

Very much worse
0

Presented as the mean change in the UPDRS scores (standard deviations).

PGI-I: Patient-rated Global Impression of Improvement; CGI-I: Clinician-rated Global Impression of Improvement.

In the APD study, for subjects rating themselves “a little better,” mean changes in UPDRS II, III, and II + III scores in the pramipexole ER group were −2.8, −8.2, and −11.1 and in the pramipexole IR group were −3.3, −9.5, and −12.8. Across a range of PGI ratings, mean changes in UPDRS II + III scores for the pramipexole ER group were −16.4 for “very much better,” −15.8 for “much better,” −11.1 for “a little better,” −9.3 for “no change,” and −7.8 for “a little worse.” In the pramipexole IR group, changes in UPDRS II + III scores were −23.2 for “very much better,” −16.8 for “much better,” −12.8 for “a little better,” −9.2 for “no change,” −5.2 for “a little worse,” and 1.9 for “much worse.” Only one subject taking pramipexole ER self-rated as “much worse” and one as “very much worse.” Only four subjects taking pramipexole IR self-rated as “much worse” and none as “very much worse.” Mean changes in UPDRS II, III, and II + III scores for placebo-treated subjects who rated themselves unchanged were −1.0, −3.0, and −4.0. Mean change in OFF time for subjects rating themselves “a little better” was −2.0 hours in the pramipexole ER group and −2.3 hours in the pramipexole IR group (Table 3). Mean change in OFF time in placebo-treated subjects who rated themselves unchanged was −1.0 hour.

Table 3: Mean changes in OFF time according to PGI-I and CGI-I ratings by treatment group in the advanced PD study.

PGI-I
(%)
OFF time hrs (S.D.)
CGI-I
(%)
OFF time hrs (S.D.)

Pramipexole ER        

Very much better
9 (6%)
−2.9 (2.5)
Very much improved
9 (6%)
−2.8 (2.2)

Much better
51 (33%)
−2.5 (3.2)
Much improved
69 (41%)
−2.7 (3.2)

A little better
66 (41%)
−2.0 (2.8)
Minimally improved
51 (32%)
−1.7 (2.8)

No change
20 (13%)
−1.3 (2.9)
No change
22 (14%)
−1.0 (3.0)

A little worse
13 (8%)
−0.6 (3.9)
Minimally worse
7 (4%)
1.3 (3.6)

Much worse
1 (0.6%)
5.3
Much worse
1 (0.6%)
0.3

Very much worse
0

Very much worse
0

Pramipexole IR        

Very much better
10 (6%)
−4.4 (1.6)
Very much improved
11 (7%)
−3.6 (2.7)

Much better
66 (39%)
−3.2 (2.6)
Much improved
77 (46%)
−3.3 (2.5)

A little better
55 (32%)
−2.3 (2.2)
Minimally improved
55 (33%)
−2.1 (2.2)

No change
27 (16%)
−1.2 (2.7)
No change
19 (11%)
−0.9 (2.8)

A little worse
10 (6%)
−1.4 (3.8)
Minimally worse
4 (2%)
0.5 (4.2)

Much worse
3 (2%)
2.3 (5.6)
Much worse
3 (2%)
2.7 (5.3)

Very much worse
0

Very much worse
0

Placebo            

Very much better
3 (2%)
−5.1 (3.6)
Very much improved
6 (4%)
−4.4 (3.2)

Much better
44 (25%)
−1.9 (3.1)
Much improved
50 (29%)
−2.3 (2.2)

A little better
65 (37%)
−1.5 (3.4)
Minimally improved
66 (39%)
−0.9 (2.9)

No change
43 (25%)
−1.0 (2.2)
No change
31 (18%)
−1.0 (2.3)

A little worse
12 (7%)
0.3 (3.6)
Minimally worse
15 (9%)
0.0 (3.6)

Much worse
7 (4%)
−0.5 (2.1)
Much worse
3 (2%)
−1.1 (2.9)

Very much worse
0

Very much worse
0

Presented as the mean change in OFF time (standard deviations).

PGI-I: Patient-rated Global Impression of Improvement; CGI-I: Clinician-rated Global Impression of Improvement.

In the EPD trial, we calculated MCIDs in the pramipexole ER group to be −1.8 for UPDRS II, −6.2 for UPDRS III, and −8.0 for UPDRS II + III and in the pramipexole IR group −2.0 for UPDRS II, −6.1 for UPDRS III, and −8.1 for UPDRS II + III (Table 4). In the APD trial, we calculated MCIDs in the pramipexole ER group to be −1.8 for UPDRS II, −5.2 for UPDRS III, and −7.1 for UPDRS II + III and in the pramipexole IR group −2.3 for UPDRS II, −6.5 for UPDRS III, and −8.8 for UPDRS II + III. In the APD trial, we calculated the MCID for OFF time to be −1.0 hours in the pramipexole ER group and −1.3 hours in the pramipexole IR group.

Table 4: The minimal clinically important difference and the substantial clinical difference in UPDRS scores in early PD and advanced PD.

Change
Pramipexole
Early PD (PGI-I data)
Advanced PD (PGI-I data)

UPDRS II
UPDRS III
UPDRS II+III
UPDRS II
UPDRS III
UPDRS II+III
OFF time (hrs)

Minimal clinically important difference
Extended release
−1.8
−6.2
        −8.0
−1.8
−5.2
−7.1
−1.0

Immediate release
−2.0
−6.1
        −8.1
−2.3
−6.5
−8.8
−1.3

Substantial clinical difference
Extended release
−3.0
−9.0
        −12.1
−3.6
−8.2
−11.8
−1.5

Immediate release
−3.2
−7.1
        −10.3
−3.9
−8.9
−12.8
−2.2

PGI-I: Patient-rated Global Impression of Improvement.

(i) Minimal clinically important difference is defined as the mean change in the outcome measure in active treatment group subjects who rated themselves “a little better” on PGI-I minus the mean change in placebo-treated subjects who rated themselves as unchanged.

(ii) Substantial clinical difference is defined as the mean change in the outcome measure in active treatment group subjects who rated themselves “much better” on PGI-I minus the mean change in placebo-treated subjects who rated themselves as unchanged.

Spearman correlation coefficients between PGI-I/CGI-I and changes in UPDRS scores and OFF time are presented in Table 5.

Table 5: Spearman correlation coefficients between PGI-I/CGI-I and changes in UPDRS scores and OFF time in patients with early PD and advanced PD.

Global improvement
Early PD
Advanced PD

UPDRS II
UPDRS III
UPDRS II+III
UPDRS II
UPDRS III
UPDRS II+III
UPDRS II ON
UPDRS II OFF
OFF time (hrs)

CGI-I
0.42
0.51
        0.54
0.33
0.4
0.42
0.19
0.36
0.31

PGI-I
0.35
0.34
        0.39
0.31
0.3
0.34
0.21
0.32
0.27

PGI-I: Patient-rated Global Impression of Improvement; CGI-I: Clinician-rated Global Impression of Improvement.

4. Discussion

Most studies to date have assessed MCID based on change in mean UPDRS scores in subjects rated minimally improved compared to baseline using CGI-I data. We believe that data derived using patient-rated self-impression of change (PGI-I) are more relevant than data derived using clinician-rated impression of change (CGI-I) because we are interested in whether subjects themselves actually feel improved. In our study, using PGI-I or CGI-I scores as the anchor yielded mostly similar results, but there were a few notable exceptions. For example, in the EPD study in the pramipexole ER group, the mean change in UPDRS II + III scores in subjects who rated themselves unchanged was −8.9 whereas the change was −3.3 in subjects who were rated unchanged by clinicians. It is possible that some of these differences could be due to differences in the wording used in the PGI-I compared to the CGI-I (“a little better” versus “minimally improved”); however, it is also possible that a larger UPDRS improvement is required for patients to feel better than for clinicians to observe improvement. Alternatively, and probably more likely, these differences might reflect rater bias in performing UPDRS scoring, with apparent improvement in UPDRS scores being recorded in subjects who are actually little changed.

In general, our data reflect greater improvement in UPDRS scores with better PGI-I and CGI-I ratings. One exception occurs in the EPD study for subjects assigned to pramipexole ER who rated themselves very much improved. We note that this category included a relatively small proportion of subjects (, 5%). Nonetheless, one might hypothesize that these subjects experienced a strong placebo effect (for PGI-I) on top of their “actual” response or that they experienced substantial benefit in areas not adequately captured by the UPDRS. The same effect is seen with CGI-I, but the amplitude is not as great as with PGI-I, which suggests that the PGI-I may have influenced the CGI-I as these are often highly correlated. However, smaller UPDRS improvements were not observed in the patients assigned to pramipexole IR in the EPD study or in either pramipexole group in the APD study. This suggests that this finding may just be spurious or possibly related to an inexact distinction between the two highest PGI-I/CGI-I categories.

Hauser and Auinger [3] previously suggested that if the mean change in the efficacy outcome measure being examined is sufficiently far from zero in placebo-treated subjects who rated themselves as unchanged, one should subtract this “placebo effect” from observed changes in active treatment groups when calculating clinically important differences. Therefore, one can define the MCID as the mean change in the outcome measure in active treatment group subjects who rate themselves “a little better” minus the mean change in placebo-treated subjects who rate themselves as unchanged. For example, in a rasagiline APD trial [3], rasagiline-treated subjects who rated themselves minimally improved recorded a reduction in “OFF” time of 1.9 hours on diaries, whereas placebo-treated subjects who rated themselves as unchanged recorded a reduction in “OFF” time of 0.9 hours, thus yielding a MCID of 1.0 hour (1.9–0.9 hours).

Using this methodology, the MCIDs observed in the EPD trial (pramipexole ER, pramipexole IR) for UPDRS II were −1.8 and −2.0, for UPDRS III −6.2 and −6.1, and for UPDRS II + III −8.0 and −8.1. In a similar analysis of data from a double-blind, prospective study of rasagiline in EPD (week 14), the MCID for UPDRS I + II + III was −3.8 [3]. This is a smaller improvement than our result (for UPDRS II + III) of approximately −8.0. This “discrepancy” is consistent with the notion that the more efficacious the treatment under study, the greater the calculated MCID, likely due to differences in the distribution of outcomes. Schrag et al. [6] evaluated data from two clinical trials of ropinirole IR in EPD based on the criterion of “minimally improved” versus baseline on the CGI-I and reported minimal clinically important change (MCIC) figures very similar to ours (UPDRS II  - 2-3 points, UPDRS III  - 5 points, and total UPDRS  - 8 points) despite the fact that these figures were derived from 6-month studies comparing ropinirole to levodopa or bromocriptine in which there were no placebo control groups and medication dosages were being escalated over time.

We provide calculated “substantial clinical differences (SCDs),” defined as the mean change in the outcome measure in active treatment group subjects who rated themselves “much better” minus the mean change in placebo-treated subjects who rated themselves as unchanged in Table 4. For early PD, our SCDs are in general agreement with those of Shulman et al. [2] for moderate and large differences as derived in a cross-sectional observational analysis of patients with all stages of PD using a variety of clinician- and patient-reported external standards. Table 4 also displays MCIDs and SCDs for advanced PD. We are not aware of other published reports of MCIDs and SCDs in advanced PD but note that in the pramipexole APD study the primary outcome variable was the change in UPDRS II + III, making MCID and SCD for UPDRS scores in APD of interest.

In APD, we found MCIDs for OFF time (pramipexole ER, pramipexole IR) of −1.0 and −1.3 hours. These are similar to the MCID figure of −1.0 hour that was derived using data from a randomized, controlled trial of rasagiline in APD [3]. In the pramipexole APD study, we found SCD for OFF time (pramipexole ER, pramipexole IR) to be −1.5 and −2.2 hours. In this case, the figures derived from the pramipexole ER and pramipexole IR groups are somewhat different, but still in the same general range.

Our data indicate that there is asymmetry regarding clinically important change for improvement versus worsening. For example, in the EPD trial, for subjects assigned to pramipexole ER who rated themselves “a little better,” UPDRS III scores improved by 7.9 points. Subjects who rated themselves “a little worse” did not experience a UPDRS worsening of 7.9 points but instead were rated improved by 3.0 points. If the change in the group of placebo subjects who rated themselves unchanged is subtracted from these figures, one finds that while the MCID for improvement (for UPDRS III in the pramipexole ER group) is an improvement of 6.2 points, the MCID for worsening is an improvement of 1.3 points. This asymmetry probably reflects the distribution of change in UPDRS scores in the treated population based on both placebo and treatment effects. The direction and degree of asymmetry probably depend on both expectation (placebo effect) and the actual efficacy of the intervention. Therefore, clinical trials of effective medications cannot be used to determine how much deterioration patients in clinical practice would need to experience over time to consider themselves meaningfully worse.

As anticipated, a range of values for MCID for improvement in EPD based on UPDRS scores is emerging. Differences in outcome appear to depend on many factors including the original study design, efficacy of the intervention, and the anchor selected. We believe the most relevant results come from trials that include a placebo control group, test interventions of mild efficacy, and depend on patient-reported outcomes such as the PGI-I. Interestingly, we found that the MCID for improvement in OFF time in the APD trial was a reduction of 1.0–1.3 hours, similar to what was observed using data from a rasagiline APD trial. Whether all studies in APD will yield similar values or whether a range will emerge based on the efficacy of the intervention remains to be seen. Additional analyses are needed from trials of highly efficacious interventions such as deep brain stimulation (DBS).

Correlations between CGI-I/PGI-I and UPDRS scores and OFF time were mostly in the moderate range. Interestingly, for both EPD and APD, the strongest correlations were between the CGI-I and UPDRS III and UPDRS II + III. This may reflect the fact that the CGI-I and UPDRS III scores are both clinician-rated. These ratings may reflect the physical appearance of the patient but may fail to account for other factors important to patients, such as nonmotor features and adverse events. Rater bias may also contribute to this effect and potentially explain why in some cases UPDRS scores suggest improvement while PGI scores indicate worsening.

The methodology used to determine MCID is imperfect and studies have provided a range of values rather than a single value. Nonetheless, MCID is useful to perform power calculations and to understand the meaning of the magnitude of change one observes in a clinical trial. In the pramipexole ER pivotal trials, MCIDs in subjects with EPD (pramipexole ER, pramipexole IR) for UPDRS II were −1.8 and −2.0, for UPDRS III −6.2 and −6.1, and for UPDRS II + III −8.0 and −8.1. MCIDs in subjects with APD for UPDRS II were −1.8 and −2.3, for UPDRS III −5.2 and −6.5, and for UPDRS II + III −7.1 and −8.8. In the APD study, we found that the MCID for OFF time (pramipexole ER, pramipexole IR) was −1.0 and −1.3 hours. The current study provides support for the hypothesis [3] that more efficacious interventions yield larger calculated MCIDs. The difference in mean change in UPDRS II + III scores for pramipexole ER compared to placebo in EPD was −7.0 [9] and the calculated MCID was −8.0 whereas the adjusted effect size for change in UPDRS I + II + III for rasagiline compared to placebo was −4.2 and the calculated MCID was −3.8 [3, 11]. The lower end of the range of MCIDs emerging from clinical trials may represent a threshold effect size that should be met to conclude that an intervention has a meaningful clinical impact. In surveying the literature to date, studies suggest that the lower limit of MCID for total UPDRS (I + II + III) is −3.8 and for change on OFF time is −1.0 hour [3].

Disclosure

Dr. Hauser has received honoraria or payments for consulting, advisory services, or speaking services in the past year from Abbott Laboratories, Allergan, Inc., AstraZeneca, Biotie Therapies Corporation, Ceregene, Inc., Chelsea Therapeutics, Inc., GE Healthcare, Impax Laboratories, Inc., Ipsen Biopharmaceuticals, Inc., Lundbeck, Med-IQ, Merck/MSD, Noven Pharmaceuticals, Inc., Straken Pharmaceuticals, Ltd., Targacept, Inc., Teva Pharmaceuticals Industries, Ltd., Teva Neuroscience, Inc., Upsher-Smith Laboratories, UCB, Inc., UCB Pharma SA, and Xenoport, Inc. Dr. Hauser’s institution has received research support in the past year from Abbott Laboratories, Addex Therapeutics, Allergan, Inc., AstraZeneca, Chelsea Therapeutics, Inc., GE Healthcare, Impax Laboratories, Inc., Ipsen Biopharmaceuticals, Inc., Merck/MSD, Merz, Michael J. Fox Foundation for Parkinson’s Research, Schering-Plough, Teva Neuroscience, Inc., UCB, Inc., and Vita-Pharm. Dr. Hauser has received royalties in the past year from University of South Florida. In addition, Dr. Hauser has consulted in litigation with lawyers representing various current and former manufacturers of welding consumables. Dr. Mizuno has served as an advisory board member for Boehringer Ingelheim and FP Pharmaceutical Company and as a consultant for Ohtsuka Pharmaceutical Company and Kyowa Hakko Kirin Pharmaceutical Company. In these roles, he has received personal compensation for his attendance at advisory board meetings. Dr. Rascol has served as consultant for Abbott, Addex, BIAL, Boehringer Ingelheim, Impax Pharmaceuticals, Lundbeck, Merck, Movement Disorders Society, Novartis, Oxford Biomedica, Schering-Plough, Teva, UCB, and Xenoport. Dr. Rascol has served on advisory boards for Abbott, Addex, Impax Pharmaceuticals, Lundbeck, Merck, Merz, Novartis, Oxford Biomedica, Schering-Plough, Teva, UCB, and Xenoport. Dr. Rascol has received honoraria from Boehringer Ingelheim, GSK, Lundbeck, MDS, Novartis, Teva, and UCB. Dr. Rascol has received grants from Agence Nationale de la Recherche (ANR), CHU de Toulouse, France-Parkinson, INSERM-DHOS Recherche Clinique Translationnelle, Michael J. Fox Foundation, Programme Hospitalier de Recherche Clinique, Boehringer Ingelheim, Lundbeck, Teva, and UCB. Dr. Poewe has received consultancy and lecture fees from Abbott, Astra Zeneca, Teva, Novartis, GSK, Boehringer Ingelheim, UCB, Orion Pharma, Merck-Serono, and Merz Pharmaceuticals in relation to clinical drug development programs for PD. Professor Barone has received honoraria as a consultant, advisory board member, or speaker at educational events for Novartis, Schwarz Pharma/UCB, Merck-Serono, Eisai, Solvay, Boehringer Ingelheim, and Lundbeck-Teva. He has received research support from Novartis, Schwarz Pharma/UCB, Merck-Serono, Solvay, and Lundbeck-Teva. He has received salary from the University of Salerno, Italy. Professor Schapira has received honoraria or undertaken consultancy work with Boehringer Ingelheim, GSK, Teva-Lundbeck, Orion-Novartis, Schwartz-Pharma, and Merck. Dr. Gordon is an employee of Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT. Dr. Debieuvre is an employee of Boehringer Ingelheim France S.A.S., Reims, France. Dr. Fräßdorf is an employee of Boehringer Ingelheim Pharmaceuticals, GmbH & Co. KG, Ingelheim, Germany.

Conflict of Interests

Drs. Hauser, Mizuno, Poewe, Barone, Schapira, and Rascol have received fees for activities related to pramipexole ER but no financial support was provided for authorship of this paper. Drs. Gordon, Debieuvre, and Fräßdorf are employees of Boehringer Ingelheim.

Authors’ Contribution

Robert A. Hauser and Mark Forrest Gordon contributed equally to this work and are coprimary authors. Dr. Hauser was responsible for conception and design; acquisition of data; analysis and interpretation of data; authorship of first draft; critical revision of the submitted publication material based on review of coauthors. Dr. Gordon was responsible for conception and design; acquisition of data; analysis and interpretation of data; administrative, technical, or material support; supervision; authorship of first draft; critical revision of the submitted publication material based on review of coauthors. Drs. Rascol and Poewe were responsible for conception and design; acquisition of data; analysis and interpretation of data; critical revision of the submitted publication material. Drs. Barone and Schapira were responsible for analysis and interpretation of data; critical revision of the submitted publication material. Dr. Mizuno was responsible for conception and design; analysis and interpretation of data; critical revision of the submitted publication material. Dr. Debieuvre was responsible for acquisition of data; analysis and interpretation of data; drafting of part of the submitted publication material; statistical expertise; and supervision. Dr. Fräßdorf was responsible for acquisition of data; analysis and interpretation of data; critical revision of the submitted publication material; and statistical expertise.

Acknowledgments

These studies were supported by Boehringer Ingelheim. The authors were fully responsible for all content and editorial decisions, were involved at all stages of paper development, and have approved the final version. The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors received no direct compensation related to the development of the paper. No medical writing assistance was used in the preparation of this paper. Boehringer Ingelheim was given the opportunity to review the paper for medical and scientific accuracy as well as intellectual property considerations.

References

L. R. Caplan, “How well does “evidence-based” medicine help neurologists care for individual patients?” Reviews in Neurological Diseases, vol. 4, no. 2, pp. 75–84, 2007.

L. M. Shulman, A. L. Gruber-Baldini, K. E. Anderson, P. S. Fishman, S. G. Reich, and W. J. Weiner, “The clinically important difference on the unified parkinson's disease rating scale,” Archives of Neurology, vol. 67, no. 1, pp. 64–70, 2010.

R. A. Hauser, P. Auinger, and On Behalf of the Parkinson Study Group, “Determination of minimal clinically important change in early and advanced Parkinson's disease,” Movement Disorders, vol. 26, no. 5, pp. 813–818, 2011.

Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease, “The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations,” Movement Disorders, vol. 18, no. 7, pp. 738–750, 2003.

Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health, Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, US Department of Health and Human Services, Rockville, Md, USA, 2006.

A. Schrag, C. Sampaio, N. Counsell, and W. Poewe, “Minimal clinically important change on the Unified Parkinson's Disease Rating Scale,” Movement Disorders, vol. 21, no. 8, pp. 1200–1207, 2006.

O. Rascol, “Defining a minimal clinically relevant difference for the Unified Parkinson's Rating Scale: an important but still unmet need,” Movement Disorders, vol. 21, no. 8, pp. 1059–1061, 2006.

R. A. Hauser, A. H. V. Schapira, O. Rascol et al., “Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease,” Movement Disorders, vol. 25, no. 15, pp. 2542–2549, 2010.

W. Poewe, O. Rascol, P. Barone et al., “Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial,” Neurology, vol. 77, no. 8, pp. 759–766, 2011.

A. H. V. Schapira, P. Barone, R. A. Hauser et al., “Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial,” Neurology, vol. 77, no. 8, pp. 767–774, 2011.

Parkinson Study Group, “A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study,” Archives of Neurology, vol. 59, pp. 1937–1943, 2002.